Chiesi Group has officially completed its acquisition of KalVista Pharmaceuticals, marking a major step in strengthening its presence in the rare disease market.
With the transaction now complete, KalVista has become a wholly owned subsidiary of Chiesi. The acquisition is expected to support the growth of Chiesi’s Rare Diseases business unit, which focuses on the research, development, and commercialization of treatments for rare and ultra-rare conditions.
The company says the acquisition will help expand patient access to innovative therapies while accelerating its impact in the rare disease space.
A key part of the acquisition is the addition of Ekterly (sebetralstat), the first and only approved oral, on-demand treatment for hereditary angioedema (HAE) attacks in patients aged 12 years and older.
Following the acquisition, Chiesi now owns Ekterly and all associated development programs.
The treatment has already received approvals in several major markets, including:
Additional regulatory applications are currently under review in important global markets. At the same time, ongoing clinical studies are evaluating the use of Ekterly in children between 2 and 11 years of age.
On June 11, 2026, Chiesi successfully completed its tender offer to acquire all outstanding shares of KalVista common stock at a price of $27.00 per share in cash.
The company accepted all validly tendered shares that had not been withdrawn before the offer expired. These shares represented approximately 77.8% of KalVista’s outstanding common stock.
After completing the tender offer, Chiesi finalized the acquisition through a merger involving one of its wholly owned subsidiaries and KalVista.
As part of the merger:
Following the completion of the transaction, KalVista’s common stock stopped trading on the Nasdaq Global Market.
Advisory Firms Involved in the Deal
Several financial and legal advisors supported the transaction.
For Chiesi:
For KalVista:
Understanding Ekterly and Its Role in HAE Treatment
Ekterly (sebetralstat) is a novel plasma kallikrein inhibitor developed for the treatment of acute hereditary angioedema attacks.
The therapy offers an oral treatment option that can be taken when an attack occurs, providing an alternative to injectable treatments commonly used in HAE management.
The medicine is approved for people aged 12 years and older and is intended to help patients manage attacks quickly after symptoms begin.
What Is Hereditary Angioedema?
Hereditary angioedema, commonly known as HAE, is a rare genetic disease caused by a deficiency or dysfunction of the C1 esterase inhibitor (C1INH) protein.
When this protein does not function properly, the kallikrein-kinin system becomes overactive, leading to episodes of severe swelling in different parts of the body.
People living with HAE may experience:
Clinical guidelines recommend treating attacks as early as possible to prevent worsening symptoms and shorten recovery time. Experts also recommend considering treatment for all attacks regardless of their location or severity.
Chiesi’s Growing Focus on Rare Diseases
The acquisition reflects Chiesi’s continued investment in rare disease treatments and innovative therapies.
The company develops and markets medicines across three major areas:
By adding KalVista and Ekterly to its portfolio, Chiesi strengthens its ability to address unmet needs in patients living with rare and complex conditions.
About Chiesi Group
Chiesi is a research-focused international biopharmaceutical company headquartered in Parma, Italy. The company has more than 90 years of experience in healthcare and operates through 31 affiliates worldwide.
Chiesi employs over 7,900 people and maintains a global research network that includes research and development hubs in:
The company is also recognized for its sustainability efforts. Chiesi operates as a certified B Corp and has adopted Benefit Corporation status in multiple countries, making its commitment to social and environmental responsibility a formal part of its business structure.
In addition, the company has announced a goal of achieving net-zero greenhouse gas emissions by 2035.